How to buy Cytosorbents Corporation stock | $8.09

Cytosorbents Corporation is a medical devices business based in the US. Cytosorbents Corporation shares (CTSO) are listed on the NASDAQ and all prices are listed in US Dollars. Cytosorbents Corporation employs 195 staff and has a trailing 12-month revenue of around 0.00.

Cytosorbents Corporation stock price (NASDAQ: CTSO)

Use our graph to track the performance of CTSO stocks over time.

Cytosorbents Corporation shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$8.09
52-week range	$7.13 - $11.68
50-day moving average	$7.78
200-day moving average	$8.80
Wall St. target price	$14.86
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.53

Buy Cytosorbents Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cytosorbents Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cytosorbents Corporation by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cytosorbents Corporation price performance over time

Historical closes compared with the close of $8.09 from 2021-05-28

1 week (2021-07-25)	N/A
1 month (2021-07-02)	10.07%
3 months (2021-05-05)	-6.90%
6 months (2021-02-01)	N/A

1 year (2020-08-01)	N/A
2 years (2019-08-01)	N/A
3 years (2018-08-01)	N/A
5 years (2016-08-01)	N/A

Cytosorbents Corporation financials

Revenue TTM	$42.9 million
Gross profit TTM	$30 million
Return on assets TTM	-10.2%
Return on equity TTM	-17.35%
Profit margin	-19.94%
Book value	$1.79
Market capitalisation	$334.6 million

TTM: trailing 12 months

Shorting Cytosorbents Corporation shares

There are currently 2.2 million Cytosorbents Corporation shares held short by investors – that's known as Cytosorbents Corporation's "short interest". This figure is 18.2% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting Cytosorbents Corporation shares can be evaluated.

Cytosorbents Corporation's "short interest ratio" (SIR)

Cytosorbents Corporation's "short interest ratio" (SIR) is the quantity of Cytosorbents Corporation shares currently shorted divided by the average quantity of Cytosorbents Corporation shares traded daily (recently around 346728.03149606). Cytosorbents Corporation's SIR currently stands at 6.35. In other words for every 100,000 Cytosorbents Corporation shares traded daily on the market, roughly 6350 shares are currently held short.

However Cytosorbents Corporation's short interest can also be evaluated against the total number of Cytosorbents Corporation shares, or, against the total number of tradable Cytosorbents Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytosorbents Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cytosorbents Corporation shares in existence, roughly 50 shares are currently held short) or 0.0555% of the tradable shares (for every 100,000 tradable Cytosorbents Corporation shares, roughly 56 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cytosorbents Corporation.

Find out more about how you can short Cytosorbents Corporation stock.

Cytosorbents Corporation share dividends

We're not expecting Cytosorbents Corporation to pay a dividend over the next 12 months.

Have Cytosorbents Corporation's shares ever split?

Cytosorbents Corporation's shares were split on a 1:25 basis on 4 December 2014. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytosorbents Corporation shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Cytosorbents Corporation shares which in turn could have impacted Cytosorbents Corporation's share price.

Cytosorbents Corporation share price volatility

Over the last 12 months, Cytosorbents Corporation's shares have ranged in value from as little as $7.13 up to $11.684. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytosorbents Corporation's is 0.2786. This would suggest that Cytosorbents Corporation's shares are less volatile than average (for this exchange).

Cytosorbents Corporation overview

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey. .

Frequently asked questions

What percentage of Cytosorbents Corporation is owned by insiders or institutions?
Currently 8.465% of Cytosorbents Corporation shares are held by insiders and 43.111% by institutions. How many people work for Cytosorbents Corporation?
Latest data suggests 195 work at Cytosorbents Corporation. When does the fiscal year end for Cytosorbents Corporation?
Cytosorbents Corporation's fiscal year ends in December. Where is Cytosorbents Corporation based?
Cytosorbents Corporation's address is: 7 Deer Park Drive, Monmouth Junction, NJ, United States, 08852 What is Cytosorbents Corporation's ISIN number?
Cytosorbents Corporation's international securities identification number is: US23283X2062 What is Cytosorbents Corporation's CUSIP number?
Cytosorbents Corporation's Committee on Uniform Securities Identification Procedures number is: 23283X107